- Individuals 18 to 49 years of age OR 65 to 85 years of age, inclusive on the day of informed consent.
- Individuals with body mass index (BMI) between 18 and 32 kg/m2, inclusive, at screening .
- Individuals who can comply with study procedures including follow-up .
This is a Phase 1, first-in-human, randomized, placebo-controlled, observer blind study. The effect of one or two doses of an investigational vaccine on safety, reactogenicity, kinetics and magnitude of the post-vaccination antibody response will be evaluated at different timepoints as compared to placebo in healthy adults. Approximately 128 evaluable subjects will be enrolled in this study; n=96 receiving investigational vaccine and n=32 receiving placebo. The study has a screening period (Day -28 to Day -1), a treatment period (Day 1 to Day 43) and a follow-up period (Day 44 to Day 202).